Pharmalot - STAT

Pharmalot By Ed Silverman

FDA threatens to fine another drug maker for failing to report clinical trial results

Pharmalot By Ed Silverman

Pharmalittle: Emergent to resume Covid-19 vaccine production; FDA OKs first interchangeable biosimilar insulin

Pharmalot By Ed Silverman

FDA approves the first interchangeable biosimilar insulin. Will it really lower the cost?

Pharmalot By Ed Silverman

Lawmakers ask Defense Department about using a controversial maneuver to lower drug prices

Pharmalot By Ed Silverman

Pharmalittle: Biogen yanks Alzheimer’s paper from JAMA over edits; Pfizer sees $33.5 billion in Covid-19 vax sales

Pharmalot By Ed Silverman

Pharmalittle: Pharma lobbies Congress on global tax proposal; the FDA doc at center of Aduhelm controversy

Pharmalot By Ed Silverman

Purdue says most creditors voted in favor of contentious bankruptcy plan

Pharmalot By Elizabeth Cooney

Pharmalittle: Biogen’s ‘symptom quiz’ for Aduhelm draws fire; most U.S. clinical trials flunk transparency rules

Pharmalot By Ed Silverman

Pharmalittle: Biogen defends its controversial Alzheimer’s drug; critics pan Pfizer plan for Covid-19 shot production in Africa

Pharmalot By Ed Silverman

Pharmalittle: Pfizer cuts deal for Covid-19 shot to be partially made in South Africa; wholesalers to pay $1.1b to NY to settle opioid suit

Pharmalot By Ed Silverman

Three pharma wholesalers reach a $1.1 billion deal with New York over the opioid crisis

Pharmalot By Ed Silverman

As a key hearing nears, Justice Department calls Purdue’s bankruptcy plan unconstitutional

Pharmalot By Ed Silverman

Pharmalittle: Wholesalers near deal over opioid litigation; pharma gives $67,400 to Peters for trying to torpedo drug pricing bill

Pharmalot By Ed Silverman

Advocates urge Biden to name patent office director that could transform drug pricing

Pharmalot By Ed Silverman

Dutch authorities fine drug maker $23 million for ‘excessive’ pricing of a rare disease drug

Pharmalot By Ed Silverman

Pharmalittle: Pfizer seeks full FDA approval for its Covid-19 vaccine; CT attorney general calls some Sacklers ‘entitled thugs’

Pharmalot By Ed Silverman

Amid Purdue bankruptcy talks, Connecticut attorney general accuses some Sacklers of intimidation

Pharmalot By Elizabeth Cooney

Pharmalittle: ICER medical experts find no benefit for Aduhelm; FDA panel votes down Fibrogen’s anemia drug

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot By Ed Silverman

Expert panel votes unanimously that Biogen Alzheimer’s drug doesn’t offer patient benefits

Pharmalot By Ed Silverman

U.K. issues record fine to drug makers for price gouging and collusion schemes

Pharmalot By Ed Silverman

Pharmalittle: FDA head admits possible missteps in Alzheimer’s drug approval; two major health systems won’t administer Biogen drug

Pharmalot By Ed Silverman

FDA scolds Amgen over a misleading ad that could deter use of biosimilar versions of its drug

Pharmalot By Ed Silverman

Pharmalittle: Half-dozen big insurers won’t cover new Alzheimer’s drug; Medicaid could spend up to $2.2 billion on the Biogen drug

Pharmalot By Ed Silverman

Most Read

States reach $26 billion deal with three wholesalers and J&J to end opioid lawsuits

Biden wants to bolster the pharma supply chain. A major generic plant closing may make that harder

Most clinical trials failed to meet U.S. transparency requirements for recently approved drugs

FDA plans to study whether pharma reps at conference exhibit booths are telling the truth

Animal rights activists get new ammunition in their battle over a controversial rodent test

Pfizer looks to widen access to Covid-19 vaccine in Africa, but advocates say it doesn’t go far enough

Up and down the ladder: The latest comings and goings

Pharmalittle: A race to develop Covid-19 pills is underway; Russian trolls target Pfizer vaccine

All Coverage

FDA threatens to fine another drug maker for failing to report clinical trial results

Pharmalittle: Emergent to resume Covid-19 vaccine production; FDA OKs first interchangeable biosimilar insulin

FDA approves the first interchangeable biosimilar insulin. Will it really lower the cost?

Lawmakers ask Defense Department about using a controversial maneuver to lower drug prices

Pharmalittle: Biogen yanks Alzheimer’s paper from JAMA over edits; Pfizer sees $33.5 billion in Covid-19 vax sales

Pharmalittle: Pharma lobbies Congress on global tax proposal; the FDA doc at center of Aduhelm controversy

Purdue says most creditors voted in favor of contentious bankruptcy plan

Pharmalittle: Biogen’s ‘symptom quiz’ for Aduhelm draws fire; most U.S. clinical trials flunk transparency rules

Pharmalittle: Biogen defends its controversial Alzheimer’s drug; critics pan Pfizer plan for Covid-19 shot production in Africa

Pharmalittle: Pfizer cuts deal for Covid-19 shot to be partially made in South Africa; wholesalers to pay $1.1b to NY to settle opioid suit

Three pharma wholesalers reach a $1.1 billion deal with New York over the opioid crisis

As a key hearing nears, Justice Department calls Purdue’s bankruptcy plan unconstitutional

Pharmalittle: Wholesalers near deal over opioid litigation; pharma gives $67,400 to Peters for trying to torpedo drug pricing bill

Advocates urge Biden to name patent office director that could transform drug pricing

Dutch authorities fine drug maker $23 million for ‘excessive’ pricing of a rare disease drug

Pharmalittle: Pfizer seeks full FDA approval for its Covid-19 vaccine; CT attorney general calls some Sacklers ‘entitled thugs’

Amid Purdue bankruptcy talks, Connecticut attorney general accuses some Sacklers of intimidation

Pharmalittle: ICER medical experts find no benefit for Aduhelm; FDA panel votes down Fibrogen’s anemia drug

Up and down the ladder: The latest comings and goings

Expert panel votes unanimously that Biogen Alzheimer’s drug doesn’t offer patient benefits

U.K. issues record fine to drug makers for price gouging and collusion schemes

Pharmalittle: FDA head admits possible missteps in Alzheimer’s drug approval; two major health systems won’t administer Biogen drug

FDA scolds Amgen over a misleading ad that could deter use of biosimilar versions of its drug

Pharmalittle: Half-dozen big insurers won’t cover new Alzheimer’s drug; Medicaid could spend up to $2.2 billion on the Biogen drug

Insulin makers and pharmacy benefit managers must face racketeering claims in a lawsuit